The prevalence of Helicobacter pylori (H. pylori) infection has exceeded 50% worldwide,
and it is considered a high-risk factor for chronic gastritis, peptic ulcer, gastric …

Aim To evaluate the efficacy and safety of vonoprazan–amoxicillin (VA) dual therapy for
radically eradicating Helicobacter pylori (H. pylori). Methods The PubMed, Cochrane …

Abstract Background According to the Maastricht VI/Florence consensus report, potassium‐
competitive acid blockers (P‐CAB) may improve Helicobacter pylori eradication treatment …

Helicobacter pylori (H. pylori) infection, a type-1 carcinogen, was closely associated with
gastric cancer (GC). Successfully eradicating H. pylori infection could reduce the incidence …

Objectives This study aimed to evaluate the efficacy, adverse events, patient compliance,
and cost of dual therapy with Ilaprazole-amoxicillin (IA) at high dose versus Ilaprazole …

Helicobacter pylori (H. pylori) infects approximately half of the population worldwide and
causes chronic gastritis, peptic ulcers, and gastric cancer. Test-and-treat strategies have …

Background: Vonoprazan has been reported to exert more potent and long-lasting gastric
acid inhibition than proton pump inhibitors, potentially leading to a greater impact on the gut …

Bismuth-containing quadruple therapy (BQT) has long been recommended for Helicobacter
pylori (H. pylori) eradication in China. Meanwhile, in the latest national consensus in China …

Background The oral cavity is considered a potential reservoir of Helicobacter pylori (H.
pylori), and the imbalance of oral microbiota directly reflects the health of the host. We aimed …

Background Vonoprazan and amoxicillin (VA) dual therapy as a mainstream Helicobacter
pylori regimen has gained momentum worldwide, but the optimum dosages remain unclear …